NephroGenex — Investor Presentation (August 2014)
24 slides from NephroGenex's investor presentation, Aug 29, 2014
Slide 1: Company Presentation September 2014
Company Presentation September 2014 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward- looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expe
Slide 3: Corporate Overview
Corporate Overview Late-stage company developing therapies that target the underlying cause of kidney disease Oral Pyridorin (Phase 3) – to slow progression of diabetic nephropathy (DN) I.V. Pyridorin (Preclinical) – to treat acute kidney injury (AKI) Oral Pyridorin for DN is in Phase 3 of devel
Slide 4: The NephroGenex Pipeline
The NephroGenex Pipeline 4 Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral bid 300 mg tablet targets pathogenic oxidative chemistries 2015 I.V. formulation for hospit
Slide 5: The NephroGenex Team
The NephroGenex Team Member Affiliation, Position Pierre Legault Director Jim Mitchum Heart to Heart International, CEO Chairman of Audit Committee Robert Seltzer Care Capital, Director Chairman of Nominating Committee Eugen Steiner, M.D. BioStratum, Director HealthCap, Partner Member Affiliation, P
Slide 6: Financial Information
Financial Information Financial Information as of June 30, 2014: 8,855,114 common shares outstanding Approximately $29.9 million in cash, cash equivalents and investments Sufficient cash balance to reach early part of 2016 Capital structure ~ 9.7 M shares (8.8M common, 0.8 Options and 0.1 warran
Slide 7: Oral Pyridorin for Diabetic Nephropathy Overview
7 Oral Pyridorin for Diabetic Nephropathy Overview
Slide 8: Oral Pyridorin Market Potential
Oral Pyridorin Market Potential DN patients progress from high risk, to early stage (microalbuminuria), to overt nephropathy (macroalbuminuria), to end stage renal disease (ESRD) and dialysis 19 M diagnosed diabetics in the US, of which 33% (6.3 M) exhibit kidney disease 2.8 M macroalbuminuria (ov
Slide 9: Pathophysiology of DN
Pathophysiology of DN Hyperglycemia increases pathogenic oxidative chemistries* Elevated levels of oxidative chemistries promote the development and progression of DN* DN is the leading cause of dialysis and chronic kidney failure Pyridorin targets pathogenic oxidative chemistries, a key underly
Slide 10: Pyridorin Mechanism of Action
Pyridorin Mechanism of Action O2/M n+ Protein Protein Protein Schiff base O2/M n+ O2/M n+ Reactive carbonyl species MGO & 3-DG and ROS O2/M n+ Protein Protein Amadori A.G.E. Protein A.G.E. Glucose Toxic carbonyl compounds Advanced glycation end-products ROS - Reactive oxygen species Advanced glycati
Slide 11: NephroGenex Phase 2a PYR-205/207
NephroGenex Phase 2a PYR-205/207 Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increase in moderate to advanced disease patients Two multi-center, randomized, double-blind, placebo-controlled trials Number of centers: 20 (U.S., Belgium, United Kingdom, Canada, South Af
Slide 12: NephroGenex Phase 2b PYR-210
NephroGenex Phase 2b PYR-210 Established SOC patients approved by FDA for Phase 3 Patients on established (or stable) standard of care (SOC) at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAAL patient population Patients not on SOC at screening exhi
Slide 13: NephroGenex Phase 2 Safety Trials
NephroGenex Phase 2 Safety Trials Pyridorin was well tolerated, had a benign safety profile, and slowed the rate of SCr increase in patients on stable SOC at screening There were no meaningful differences between groups in Aes • There were increases in diarrhea and constipation with the higher Pyr
Slide 14: PIONEER Pyridorin Phase 3 Trials Protocol
PIONEER Pyridorin Phase 3 Trials Protocol Objective: Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population Baseline SCr from 1.3 to 3.0 mg/dL with a PCR >1,200 mg
Slide 15: PIONEER Pyridorin Phase 3 Trials Protocol Endpoints
PIONEER Pyridorin Phase 3 Trials Protocol Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: A Serum Creatinine
Slide 16: PIONEER Trial Interim Analysis
PIONEER Trial Interim Analysis The Company expects to conduct an interim analysis after all 600 patients have received at least 6 months of study drug The analysis will be event-based and conducted by an independent third party biostatistician One of the following three outcomes will be delivered to
Slide 17: Exclusivity Patents and New Chemical Entity (NCE)
Exclusivity Patents and New Chemical Entity (NCE) U.S. Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension) Method of manufacture patent February 2025 NCE - 5 year exclusivity Europe Method of use (including patient population
Slide 18: Corporate Summary
Corporate Summary Experienced management team focused on clinical success Diabetic nephropathy represents a large and growing unmet need Oral Pyridorin could potentially treat as many as 10 M patients, more than half of the diabetic population in the U.S. No FDA approved alternative treatments for
Slide 19: Appendix
Appendix i) NephroGenex
Slide 20: Pyridorin Phase 2a Program PYR-206
Pyridorin Phase 2a Program PYR-206 Multi-center, randomized, double-blind, placebo-controlled trial Number of centers: 46 Location of centers: U.S. Dose: 50mg BID x 24 weeks Study objectives: assess safety, tolerability and biological activity Diabetic patients with DN due to type 1 or type
Slide 21: Clinical Results PYR-206 Mild to Moderate Diabetic Nephropathy
Clinical Results PYR-206 Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Pyridorin at a 50 mg bid dose is well tolerated and slows the rate of SCr increase in mild to moderate disease patients Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood pressure
Slide 22: Clinical Results PYR-205/207 Moderate to Advanced Diabetic Nephropathy
Clinical Results PYR-205/207 Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increase in mild to moderate disease patients Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood
Slide 23: Clinical Results PYR-210 Patients With and Without SOC
Clinical Results PYR-210 Type 2 Diabetic Nephropathy Patients With and Without SOC 1at screening – 300 & 150 mg bid Patients on SOC at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAAL patient population Patients not on SOC at screening exhibit highe
Slide 24: I.V. Pyridorin for Acute Kidney Injury Rationale
Rationale Pyridorin targets specific pathogenic oxidative chemistries that emerge in diabetes These pathogenic oxidative chemistries also emerge in acute kidney injury caused by: − Reperfusion injury in CV surgery − Contrast media in angiography − Severe AKI may result in acute renal failure (AR